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Modern high-throughput experiments provide a rich resource to investigate causal determi-
nants of disease risk. Mendelian randomization (MR) is the use of genetic variants as
instrumental variables to infer the causal effect of a speciﬁc risk factor on an outcome.
Multivariable MR is an extension of the standard MR framework to consider multiple potential
risk factors in a single model. However, current implementations of multivariable MR use
standard linear regression and hence perform poorly with many risk factors. Here, we propose
a two-sample multivariable MR approach based on Bayesian model averaging (MR-BMA) that
scales to high-throughput experiments. In a realistic simulation study, we show that MR-BMA
can detect true causal risk factors even when the candidate risk factors are highly correlated.
We illustrate MR-BMA by analysing publicly-available summarized data on metabolites to
prioritise likely causal biomarkers for age-related macular degeneration.
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Mendelian randomization (MR) is the use of geneticvariants to infer the presence or absence of a causaleffect of a risk factor on an outcome. Under the
assumption that the genetic variants are valid instrumental
variables, this causal effect can be consistently inferred even in the
presence of unobserved confounding factors1. The instrumental
variable assumptions are illustrated by a directed acyclic graph as
shown in Fig. 12.
Recent years have seen an explosion in the size and scale of
data sets with biomarker data from high-throughput experiments
and concomitant genetic data. These biomarkers include pro-
teins3, blood cell traits4, metabolites5 or imaging phenotypes such
as from cardiac image analysis6. High-throughput experiments
provide ideal data resources for conducting MR investigations in
conjunction with case-control data sets providing genetic asso-
ciations with disease outcomes (such as from CARDIo-
GRAMplusC4D for coronary artery disease7, DIAGRAM for type
2 diabetes8, or the International Age-related Macular Degenera-
tion Genomics Consortium [IAMDGC] for age-related macular
degeneration9). In addition to their untargeted scope, one speciﬁc
feature of high-throughput experiments is a distinctive correla-
tion pattern between the candidate risk factors shaped by latent
biological processes.
Multivariable MR is an extension of standard (univariable) MR
that allows multiple risk factors to be modelled at once10.
Whereas univariable MR makes the assumption that genetic
variants speciﬁcally inﬂuence a single risk factor, multivariable
MR makes the assumption that genetic variants inﬂuence a set of
multiple measured risk factors and thus accounts for measured
pleiotropy. Our aim is to use genetic variation in a multivariable
MR paradigm to select which risk factors from a set of related and
potentially highly correlated candidate risk factors are causal
determinants of an outcome. Existing methods for multivariable
MR are designed for a small number of risk factors and do not
scale to the dimension of high-throughput experiments. We
therefore seek to develop a method for multivariable MR that can
select and prioritize biomarkers from high-throughput experi-
ments as risk factors for the outcome of interest. In this context
we propose a Bayesian model averaging approach (MR-BMA)
that scales to the dimension of high-throughput experiments and
enables risk factor selection from a large number of candidate risk
factors. MR-BMA is formulated on two-sample summarized
genetic data which is publicly available and allows the sample size
to be maximized.
To illustrate our approach, we analyse publicly available
summarized data from a metabolite genome-wide association
study (GWAS) on nearly 25,000 participants to rank and prior-
itise metabolites as potential biomarkers for age-related macular
degeneration. Data are available on genetic associations with 118
circulating metabolites measured by nuclear magnetic resonance
(NMR) spectroscopy11 from http://computationalmedicine.ﬁ/
data#NMR_GWAS. This NMR platform provides a detailed
characterisation of lipid subfractions, including 14 size categories
of lipoprotein particles ranging from extra small (XS) high den-
sity lipoprotein (HDL) to extra-extra-large (XXL) very low
density lipoprotein (VLDL). For each lipoprotein category,
measures are available of total cholesterol, triglycerides, phos-
pholipids, and cholesterol esters, and additionally the average
diameter of the lipoprotein particles. Apart from lipoprotein
measurements, this metabolite GWAS estimated genetic asso-
ciations with amino acids, apolipoproteins, fatty and ﬂuid acids,
ketone bodies and glycerides. We assess the performance of our
proposed method in a simulation study with scenarios motivated
by the metabolite GWAS and by publicly available summary data
on blood cell traits measured on nearly 175,000 participants4.
Results
Multivariable Mendelian randomization and risk factor selec-
tion. Standard MR requires genetic variants to be speciﬁc in their
associations with a single risk factor of interest, and does not
allow genetic variants to have pleiotropic effects on other risk
factors on competing causal pathways. Multivariable MR allows
genetic variants to be associated with multiple risk factors, pro-
vided these risk factors are measured and included in the analysis.
Hence multivariable MR allows for ‘measured pleiotropic
effects’10,12. As illustration, multivariable MR can be considered
as an extension of the standard MR paradigm (Fig. 1) to model
not one, but multiple risk factors (Fig. 2).
We consider a two-sample framework, where the genetic
associations with the outcome (sample 1) are regressed on the
genetic associations with all the risk factors (sample 2) in a
multivariable regression which is implemented in an inverse-
variance weighted (IVW) linear regression. Each genetic variant
contributes one data point (or observation) to the regression
model. Weights in this regression model are proportional to the
inverse of the variance of the genetic association with the
outcome. This is to ensure that genetic variants having more
precise association estimates receive more weight in the analysis.
The causal effect estimates from multivariable MR represent the
direct causal effects of the risk factors in turn on the outcome
when all the other risk factors in the model are held constant12,13
and Supplementary Fig. 1). Including multiple risk factors into a
single model allows genetic variants to have pleiotropic effects on
the risk factors in the model referred to as “measured
pleiotropy”14.
However, the current implementation of multivariable MR is not
designed to consider a high-dimensional set of risk factors and is not
suitable to select biomarkers from high-throughput experiments.
To allow joint analysis of biomarkers from high-throughput
experiments in multivariable MR, we cast risk factor selection as
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Fig. 1 Directed acyclic graph of instrumental variable assumptions made
in univariable Mendelian randomization. G= genetic variant(s), X= risk
factor, Y = outcome, U= confounders, θ= causal effect of interest.
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Fig. 2 Directed acyclic graph of instrumental variable assumptions made
in multivariable Mendelian randomization. G= genetic variants, Xj = risk
factor j for j ¼ 1; ¼ ; d, Y = outcome, U= confounders, θj = causal effect of
risk factor j.
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variable selection in the same weighted linear regression model as
in the IVW method. Formulated in a Bayesian framework (for
full details we refer to the Methods section) we use independence
priors and closed-form Bayes factors to evaluate the posterior
probability (PP) of speciﬁc models (i.e. one risk factor or a
combination of multiple risk factors). In high-dimensional
variable selection, the evidence for one particular model can be
small because the model space is very large and many models
might have comparable evidence. This is why MR-BMA uses
Bayesian model averaging (BMA) and computes for each risk
factor its marginal inclusion probability (MIP), which is deﬁned
as the sum of the posterior probabilities over all models where the
risk factor is present. MR-BMA reports the model-averaged
causal effects (MACE), representing conservative estimates of the
direct causal effect of a risk factor on the outcome averaged across
these models. These estimates can be used to compare risk factors
or to interpret effect directions, but should not be interpreted
absolutely. As we show in a simulation study based on real
biomarker data, MR-BMA provides effect estimates biased
towards the Null when there is a causal effect but reduces the
variance of the estimate, trading bias for reduced variance.
Consequently, MR-BMA enables a better and more stable
detection of the true causal risk factors than either the
conventional IVW method or other variable selection methods.
Detection of invalid and inﬂuential instruments. Invalid
instruments may be detected as outliers with respect to the ﬁt of
the linear model. Outliers may arise for a number of reasons, but
they are likely to arise if a genetic variant has an effect on the
outcome that is not mediated by one or other of the risk factors—
an unmeasured pleiotropic effect. To quantify outliers we use the
Q-statistic, which is an established tool for identifying hetero-
geneity in meta-analysis15. More precisely, to pinpoint speciﬁc
genetic variants as outliers we use the contribution q of the var-
iant to the overall Q-statistic, where q is deﬁned as the weighted
squared difference between the observed and predicted associa-
tion with the outcome.
Even if there are no outliers, it is advisable to check for
inﬂuential observations and re-run the approach omitting that
inﬂuential variant from the analysis. If a particular genetic variant
has a strong association with the outcome, then it may have undue
inﬂuence on the variable selection, leading to a model that ﬁts that
particular observation well, but other observations poorly. To
quantify inﬂuential observations, we suggest to use Cook’s distance
(Cd)16. We illustrate the detection of inﬂuential points and outliers
in the applied example and provide more details in the Methods.
Simulation results. To assess the performance of the proposed
method, we perform a simulation study in three scenarios based
on real high-dimensional data. We compare the performance of
the conventional approach (Multivariable IVW regression), the
Lars17, Lasso, and Elastic Net18 penalised regression methods
developed for high-dimensional regression models, MR-BMA,
and the model with the highest posterior probability from the
BMA procedure (best model). We seek to evaluate two aspects of
the methods: (1) how well can the methods select the true causal
risk factors, and (2) how well can the methods estimate causal
effects. Risk factor selection is evaluated using the receiver
operating characteristic (ROC) curve, where the true positive rate
is plotted against the false positive rate. True positives are deﬁned
as the risk factors in the generation model that have a non-zero
causal effect. Causal estimation is evaluated by calculating the
mean squared error (MSE) of estimates, which is deﬁned as
the squared difference between the estimated causal effect and the
true causal effect. The MSE of an estimator decomposes into the
sum of its squared bias and its variance.
Genetic associations with the risk factors are obtained from
three different scenarios. Two scenarios are based on the NMR
metabolite GWAS by ref. 11, where we use as instrumental
variables n ¼ 150 independent genetic variants that were
associated with any of three composite lipid measurements
(LDL cholesterol, triglycerides or HDL cholesterol) at a genome-
wide level of signiﬁcance (p < 5 ´ 108) in a large meta-analysis of
the Global Lipids Genetics Consortium19. In Scenario 1, we
consider a small set of d ¼ 12 randomly selected risk factors, and
in Scenario 2 a larger set of d ¼ 92 risk factors. Scenario 3 is
based on publicly available summary data on d ¼ 33 blood cell
traits measured on nearly 175,000 participants4. Using all genetic
variants that were genome-wide signiﬁcant for any blood cell
trait, we have n ¼ 2667 genetic variants as instrumental variables.
For each scenario, we generate the genetic associations for the
outcome based on four random risk factors having a positive
effect in Setting A and on eight random risk factors, of which four
have a positive and four have a negative effect, in Setting B. In
addition, we vary the proportion of variance in the outcome
explained by the causal risk factors. Each simulation setting is
repeated 1000 times. Full detail of the generation of the simulated
outcomes is given in the Supplementary Methods.
Looking at a small set of d ¼ 12 risk factors in the NMR
metabolite data of which four risk factors are true causal ones
(Scenario 1, Setting A), we see that MR-BMA is dominating all
other methods in terms of area under the ROC curve (see Fig. 3a).
Next best methods are Lasso, Elastic Net, the Bayesian best model
and Lars. The standard IVW method gives the worst performance.
Similar results were obtained when varying the variance in the
outcome explained by the risk factors (Setting A in Supplementary
Fig. 3 and Setting B in Supplementary Fig. 4). With respect to the
MSE of estimates (Table 1), MR-BMA has the lowest MSE in
almost all scenarios followed by Elastic Net, Lasso, the Bayesian best
model, and then Lars. Elastic Net has the lowest MSE for R2 ¼ 0:5
in setting B. The highest MSE is seen for the IVW method, which
provides unbiased estimates, as can be seen in Supplementary
Figs. 5 and 6, but at the price of a high variance. As can be seen
from Supplementary Table 1, all estimation methods except the
IVW are biased conservatively towards the Null when there is a true
causal effect. Yet, all causal effect estimates are unbiased when there
is no causal effect. Supplementary Table 2 (Setting A) and
Supplementary Table 3 (Setting B) provide the mean and the
standard deviation of the causal effect estimates, which conﬁrm
the large standard deviation of the IVW estimate compared with
the other approaches.
When increasing the number of risk factors to d ¼ 92 while
keeping the number of true causal risk factors constant to four
(Scenario 2, Setting A), the standard IVW method fails to
distinguish between true causal and false causal risk factors and
provides a ranking of risk factors which is nearly random as shown
in the ROC curve in Fig. 3b and Supplementary Figs. 7 and 8.
Despite being unbiased (see Supplementary Figs. 9 and 10,
Supplementary Tables 1, 2 and 3), the variance of the IVW
estimates is large and prohibits better performance. In contrast, Lars,
Lasso, Elastic Net and MR-BMA provide causal estimates which are
biased towards zero, but have much reduced variance compared
with the IVW estimates. The Lasso provides sparse solutions with
many of the causal estimates set to zero. This allows the Lasso and
Elastic Net to have relatively good performance at the beginning of
the ROC curve, but their performance weakens when considering
more risk factors. The best performance in terms of the ROC
characteristics is observed for MR-BMA. In terms of MSE (Table 1),
the dominant role of the variance of the IVW estimate becomes
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again apparent as the IVW method has a thousand times larger
MSE than MR-BMA, which has the lowest MSE for all scenarios
considered. Similarly to earlier results on the bias of the effect
estimates we ﬁnd that the IVW is unbiased when there is a causal
effect, while the other methods designed for high-dimensional
settings are conservatively biased towards the null, and only
unbiased when there is no causal effect (Supplementary Table 1).
In the blood cell trait data (Scenario 3), MR-BMA has again the
lowest MSE, followed by the regularised regression approaches
and the best model in the Bayesian approach. Despite a large
sample size (n ¼ 2667) and comparatively low dimension of the
risk factor space (d ¼ 33), the IVW approach is the only unbiased
method at the cost of an inferior detection of true positive risk
factors (Supplementary Figs. 12 and 13) and a large variance
(Supplementary Figs. 14 and 15, Supplementary Tables 2 and 3),
and consequently a MSE which is in a magnitude of a hundred
larger than other methods designed for high-dimensional data
analysis (Table 1).
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Fig. 3 Receiver operating characteristic (ROC) curve for simulation study on metabolite GWAS. ROC curves plotting the true positive rate against the
false positive rate for a a small number of risk factors ðd ¼ 12Þ of which four have true positive effects (Scenario 1, Setting A) and for b a large number of
risk factors ðd ¼ 92Þ of which four have true positive effects (Scenario 2, Setting A). Proportion of variance explained (R2) is set to 0.3.
Table 1 Mean squared error (MSE) of the causal effect estimates from the competing methods on the NMR metabolite and blood
cell trait data.
Setting A Setting B
R2: 0.1 0.3 0.5 0.1 0.3 0.5
Scenario 1:
IVW 0.6727 0.1675 0.0784 0.5949 0.1619 0.0629
Lars 0.1292 0.0447 0.0298 0.1559 0.0648 0.0372
Lasso 0.0604 0.0289 0.0162 0.1046 0.0503 0.0307
Elastic Net 0.0673 0.0300 0.0162 0.1161 0.0480 0.0287
MR-BMA 0.0340 0.0175 0.0105 0.0534 0.0368 0.0306
Best model 0.0717 0.0320 0.0156 0.0921 0.0514 0.0376
Scenario 2:
IVW 22.9516 6.0594 2.6257 23.2495 5.7715 2.4802
Lars 0.0354 0.0367 0.0094 0.0321 0.0212 0.0143
Lasso 0.0064 0.0047 0.0039 0.0105 0.0086 0.0074
Elastic Net 0.0064 0.0044 0.0034 0.0098 0.0078 0.0067
MR-BMA 0.0051 0.0039 0.0032 0.0088 0.0076 0.0063
Best model 0.0114 0.0081 0.0061 0.0150 0.0121 0.0096
Scenario 3:
IVW 1.6200 0.4272 0.1742 2.3140 0.6208 0.2566
Lars 0.3461 0.1151 0.0482 0.5892 0.1669 0.0844
Lasso 0.0161 0.0067 0.0040 0.0378 0.0225 0.0166
Elastic Net 0.0168 0.0074 0.0044 0.0451 0.0224 0.0169
BMA 0.0066 0.0034 0.0019 0.0235 0.0165 0.0149
Best model 0.0128 0.0051 0.0027 0.0444 0.0242 0.0177
We mark in bold font the lowest MSE in each experimental setting. Scenario 1: NMR metabolites, d= 12 risk factors, Scenario 2: NMR metabolites, d= 92 risk factors, and Scenario 3: blood cell traits, d=
33 risk factors. Setting A includes four true causal risk factors which increase the risk and Setting B includes eight true causal risk factors of which half are protective and the other half increases the risk
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Metabolites as risk factors for age-related macular degenera-
tion. Next we demonstrate how MR-BMA can be used to select
metabolites as causal risk factors for age-related macular degen-
eration (AMD). AMD is a painless eye-disease that ultimately
leads to the loss of vision. AMD is highly heritable with an
estimated heritability of up to 0.71 for advanced AMD in a twin
study20. A GWAS meta-analysis has identiﬁed 52 independent
common and rare variants associated with AMD risk at a level of
genome-wide signiﬁcance9. Several of these regions are linked to
lipids or lipid-related biology, such as the CETP, LIPC and APOE
gene regions21. Lipid particles are deposited within drusen in the
different layers of Bruch’s membrane in AMD patients21. A
recent observational study has highlighted strong associations
between lipid metabolites and AMD risk22.
This evidence for lipids as potential risk factor for AMD has
motivated a multivariable MR analysis which has shown that
HDL cholesterol may be a putative risk factor for AMD, while
there was no evidence of a causal effect for LDL cholesterol and
triglycerides23. Here, we extend this analysis to consider not just
three lipid measurements, but a wider and more detailed range of
d ¼ 30 metabolite measurements to pinpoint potential causal
effects more speciﬁcally. As summary-level data we use d ¼ 30
metabolites as measured in the metabolite GWAS described
earlier11 for the same lipid-related instrumental variants as
described previously. All of these metabolites have at least one
genetic variant used as an instrumental variable that is genome-
wide signiﬁcant and no genetic associations of metabolites are
stronger correlated than r ¼ 0:985. First, we prioritise and rank
risk factors by their marginal inclusion probability (MIP) from
MR-BMA using σ2 ¼ 0:25 as prior variance and p ¼ 0:1 as prior
probability, corresponding to a priori three expected causal risk
factors. Secondly, we perform model diagnostics based on the best
models with posterior probability >0:02.
When including all genetic variants available in both the NMR
and the AMD summary data (n ¼ 148), the top risk factor with
respect to its MIP (Supplementary Table 4A) is LDL particle
diameter (LDL.D, MIP= 0.526). All other risk factors have
evidence less than MIP< 0:25. In order to check the model ﬁt,
we consider the best individual models (Supplementary Table 4B)
with posterior probability >0:02. For illustration, we present here
the predicted associations with AMD based on the best model
including LDL.D, and TG content in small HDL (S.HDL.TG)
against the observed associations with AMD. We colour code
genetic variants according to their q-statistic (Fig. 4a and
Supplementary Fig. 16A, Supplementary Table 5) and Cook’s
distance (Fig. 4b and Supplementary Fig. 16B, Supplementary
Table 6). First, the q-statistic indicates two variants, rs492602 in
the FUT2 gene region and rs6859 in the APOE gene region, as
outliers in all best models. Second, the genetic variant with the
largest Cook’s distance (Cd= 0.871–1.087) consistently in all
models investigated is rs261342 mapping to the LIPC gene region.
This variant has been indicated previously to have inconsistent
associations with AMD compared with other genetic variants23,24.
We repeat the analysis without the three inﬂuential and/or
heterogeneous variants (n ¼ 145), and report the ten risk factors
with the largest marginal inclusion probability in Table 2 and the
full results in Supplementary Table 7. The top two risk factors are
total cholesterol in extra-large HDL particles (XL.HDL.C,
MIP ¼ 0:700) and total cholesterol in large HDL particles (L.
HDL.C, MIP ¼ 0:229). XL.HDL.C and L.HDL.C were strongly
correlated (r ¼ 0:80), and models including both have very low
evidence as can be seen in Table 3 which gives the posterior
probability of individual models. Supplementary Fig. 17 shows
the scatterplots of the genetic associations with each of these two
risk factors individually against the genetic associations with
AMD risk. We select the ﬁve individual models with a posterior
probability >0:02 to inspect the model ﬁt (Supplementary Figs. 18
and 19). This time, no genetic variant has a consistently large
q-statistic (Supplementary Table 8) or Cook’s distance (Supple-
mentary Table 9). Repeating the analysis without the largest
inﬂuential point, rs5880 in the CETP gene region, or the strongest
outlier, rs103294 in the AC245884.7 gene region, did not impact
the ranking of the risk factors. We tested the robustness of the
results with respect to a wide range of prior variance and prior
probability parameters; results did not change substantially
(Supplementary Tables 10 and 11).
We also applied Lars, Lasso and Elastic Net after excluding
outliers and inﬂuential points (n ¼ 145). Lars showed the largest
regression coefﬁcient for L.HDL.C including 11 risk factors. Lasso
selected four risk factors with the largest regression coefﬁcient for
XL.HDL.C, while Elastic Net selected ten risk factors with the
largest regression coefﬁcient for L.HDL.C. Full results for the
competing methods are given in Supplementary Tables 12–15. A
disadvantage of regularised regression approaches is that risk
factor selection is binary; risk factors are either included in the
model or set to have a coefﬁcient zero. The magnitude of
regularised regression coefﬁcients does not rank risk factors
according to their strength of evidence for inclusion in the model.
The detection of inﬂuential points in the initial analysis highlights
rs26134, a genetic variant in the LIPC gene region, which had a
strong impact on the analysis. Figure 5 shows the model diagnostics
of the highest ranked model excluding outlying and inﬂuential
points (XL.HDL.C as the sole risk factor), with the variant in the
LIPC gene region also plotted. This particular variant exhibits a
distinct, potentially pleiotropic, effect. While all other variants
support that XL.HDL.C increases the risk of AMD, this particular
variant has the opposite direction of association with AMD risk as
that predicted by its association with XL.HDL.C. Further functional
and ﬁne-mapping studies of this region are needed to understand
the contrasting association of this variant with AMD risk.
These results conﬁrm previous studies23,24 that identiﬁed HDL
cholesterol as a putative risk factor for AMD and draw the
attention to extra-large and large HDL particles. A recent
observational study22 supports our ﬁnding that extra-large HDL
particles have an important role in the pathogenesis of AMD.
Discussion
We here introduce MR-BMA, an approach for multivariable MR
which allows for the analysis of high-throughput experiments. This
model averaging procedure prioritises and selects causal risk factors
in a Bayesian framework from a high-dimensional set of related
candidate risk factors. As is common for statistical techniques for
variable selection, MR-BMA does not provide unbiased estimates.
However, as shown in the simulation study, causal estimates from
MR-BMA have reduced variance and thus MR-BMA improves over
unbiased approaches, like the IVW method, in terms of mean
squared error and detection of true risk factors. The primary aim of
this work is to detect causal risk factors rather than to unbiasedly
estimate the magnitude of their causal effects. MR-BMA is a mul-
tivariable MR approach that can analyse a high-dimensional set of
risk factors. When analysing many risk factors jointly one impor-
tant implicit assumption of MR-BMA is sparsity, i.e., the proportion
of true causal risk factors compared with all risk factors considered
is small. Since MR-BMA evaluates all possible combinations of risk
factors exhaustively or all relevant combinations of risk factors in a
shotgun stochastic search there is an upper bound for the max-
imum model size in order to keep the computation tractable.
Sparsity is a common assumption for high-throughput data and we
have seen in the applied example that the best models only
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contained one to three metabolites as risk factors despite allowing
for a model size of up to twelve risk factors. Yet this is an important
aspect of the algorithm and the maximum model size should be
adjusted if models including many risk factors are expected or
evidenced in the data.
We demonstrated the approach with application to a dataset of
NMR metabolites, which included predominantly lipid mea-
surements, using variants associated with lipids as instrumental
variables. Previous MR analysis23,24 including three lipid mea-
surements from the Global Lipids Genetics Consortium19 have
identiﬁed HDL cholesterol as potential risk factor for AMD. Our
approach to multivariable MR reﬁned this analysis and conﬁrmed
HDL cholesterol as a potential causal risk factor for AMD, further
pinpointing that large or extra-large HDL particles are likely to be
driving disease risk. Other areas of application where this method
could be used include imaging measurements of the heart and
coronary artery disease, body composition measures and type 2
diabetes, or blood cell traits and atherosclerosis. As multivariable
MR accounts for measured pleiotropy, this approach facilitates
the selection of suitable genetic variants for causal analyses. In
each case, it is likely that genetic predictors of the set of risk
factors can be found, even though ﬁnding speciﬁc predictors of,
for example, particular heart measurements from cardiac ima-
ging, may be difﬁcult given widespread pleiotropy25. MR-BMA
allows a more agnostic and hypothesis-free approach to causal
inference, allowing the data to identify the causal risk factors.
Multivariable MR estimates the direct effect of a risk factor on
the outcome and not the total effect as estimated in standard
univariable MR. This is in analogy with multivariable regression
where the regression coefﬁcients represent the association of each
variable with the outcome when all others are held constant.
Having said this, the main goal of our approach is risk factor
selection, and not the precise estimation of causal effects, since
the variable selection procedure shrinks estimates towards the
null. This results in causal effect estimates being biased towards
the Null when there is a causal effect and unbiased estimates
when there is no causal effect. If there are mediating effects
between the risk factors, then this approach will identify the risk
factor most proximal to and has the most direct effect on an
outcome. For example, if the risk factors included would form a
signalling cascade (Supplementary Fig. 1b) then our approach
would identify the downstream risk factor in the cascade with the
direct effect on the outcome and not the upstream risk factors in
the beginning of the cascade. Hence, a risk factor may be a cause
of the outcome, but if its causal effect is mediated via another risk
factor included in the analysis, then it will not be selected in the
multivariable MR approach.
Our approach is formulated in a Bayesian framework. Parti-
cular care needs to be taken when choosing the hyper-parameter
for the prior probability which relates to the a priori expected
number of causal risk factors. In the applied example the results
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Fig. 4 Diagnostic plots for outliers and inﬂuential genetic variants. Plotting the predicted associations with AMD based on the model including LDL.D,
and S.HDL.TG (x-axis) against the observed associations with AMD (y-axis) showing all n ¼ 148 genetic variants. This is the highest-ranking model when
keeping outlying and inﬂuential genetic variants in the analysis. The colour code shows: a the q-statistic for outliers and b Cook's distance for the inﬂuential
points. Any genetic variant with q-value larger than 10 or Cook's distance larger than the median of the relevant F-distribution is marked by a label
indicating the gene region.
Table 2 Ranking of risk factors for age-related macular
degeneration (AMD) according to their marginal inclusion
probability (MIP) after exclusion of outlying and inﬂuential
variants (n ¼ 145).
Risk factor Marginal inclusion
probability (MIP)
Model-averaged
causal effect
θ^MACE
1 XL.HDL.C 0.7 0.344
2 L.HDL.C 0.229 0.087
3 HDL.D 0.087 0.022
4 XS.VLDL.TG 0.082 −0.019
5 LDL.D 0.074 −0.018
6 IDL.TG 0.066 −0.012
7 XXL.VLDL.TG 0.063 0.018
8 S.VLDL.TG 0.062 −0.014
9 Serum.TG 0.061 −0.014
10 Serum.C 0.054 −0.011
Results are given after excluding genetic variants in the APOE, FUTC, and LIPC regions. θ^MACE is
the model-averaged causal effect of a risk factor
HDL.D HDL diameter, IDL.TG triglycerides in IDL, L.HDL.C total cholesterol in large HDL, LDL.D
LDL diameter, Serum.C serum total cholesterol, Serum.TG serum total triglycerides, S.VLDL.C
total cholesterol in small VLDL, S.VLDL.TG triglycerides in small VLDL, XS.VLDL.TG triglycerides
in very small VLDL, XL.HDL.C total cholesterol in very large HDL
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were robust to a wide range of prior speciﬁcations for the para-
meter as seen in Supplementary Table 10. In addition, the prior
variance of the causal parameters needs to be speciﬁed and tested
for robustness as we show in the Supplementary Table 11.
When genetic variants are weak predictors for the risk factors,
this can introduce weak instrument bias. In univariable two-
sample MR, any bias due to weak instruments is towards the null
and does not lead to inﬂated type 1 error rates26. However, in
multivariable MR, weak instrument bias can be in any direction
(see Methods), although bias will tend to zero as the sample size
increases and consequently the instrument strength increases.
Selection of risk factors is only possible if there are genetic var-
iants that are predictors of these risk factors. One of the biggest
challenges of multivariable MR is the design of a meaningful
study, in particular the choice of both, the genetic variants and
the risk factors. The design of the study is important for the
interpretation of the risk factors prioritised: The ranking of risk
factors is conditional on the genetic variants used. For instance, in
our applied example we ﬁnd evidence for extra-large and large
HDL cholesterol concentration given that we used lipid-related
genetic variants as instrumental variables. We recommend to
include only risk factors which have at least one, and ideally
multiple genetic variants that act as strong instruments. Caution
is needed for the interpretation of null ﬁndings, particularly in
our example for non-lipid risk factors, as these might be
deprioritised in terms of statistical power by our choice of genetic
variants. The instrument selection and general study design are
essential for the MR-BMA approach and we strongly recommend
the user to be critical in the choice of genetic variants and risk
factors. Moreover, similar to standard MR we urge to perform
model checks and be transparent in the presentation of the
removal of outlier/inﬂuential genetic variants.
A further requirement for multivariable MR is that the genetic
variants can distinguish between risk factors12. We recommend to
check the correlation structure between genetic associations for
the selected genetic variants and to include no pair of risk factors
which is extremely strongly correlated. In the applied example, we
included only risk factors with an absolute correlation <0.99. As
we were not able to include more than three measurements for
each lipoprotein category (cholesterol content, triglyceride con-
tent, diameter), care should be taken not to overinterpret ﬁndings
in terms of the speciﬁc measurements included in the analysis
rather than those correlated measures that were excluded from
the analysis (such as phospholipid and cholesterol ester content).
Another assumption of multivariable MR is that there is no
unmeasured horizontal pleiotropy. This means that the variants
do not inﬂuence the outcome except via the measured risk fac-
tors. The assumption of no horizontal pleiotropy is a common
and untestable assumption in MR. It is an active area of research
to robustify MR against violations of this assumption. Some of
these robust methods for MR make a speciﬁc assumption about
the behaviour of pleiotropic variants, such as MR-Egger27, which
assumes pleiotropic effects are uncorrelated from the genetic
associations with the risk factor—the InSIDE assumption. Other
methods exclude outlying variants as they are potentially pleio-
tropic such as MR-PRESSO28. In multivariable MR, pleiotropic
variants can be detected as outliers to the model ﬁt. Here we
quantify outliers using the q-statistic. Outlier detection in stan-
dard univariable MR can be performed by model averaging where
different subsets of instruments are considered29,30, assuming
Table 3 Ranking of models (sets of risk factors) for age-related macular degeneration (AMD) according to their posterior
probability (PP) after exclusion of outlying and inﬂuential variants (n ¼ 145).
Models or sets of risk factor(s) Posterior probability (PP) Model-speciﬁc causal estimates θ^γ
1 XL.HDL.C 0.156 0.509
2 L.HDL.C 0.078 0.384
3 XL.HDL.C,XS.VLDL.TG 0.026 0.457,−0.181
4 IDL.TG,XL.HDL.C 0.025 −0.179,0.495
5 HDL.D 0.023 0.359
6 Serum.C,XL.HDL.C 0.019 −0.183,0.573
7 S.VLDL.TG,XL.HDL.C 0.015 −0.172,0.443
8 S.VLDL.C,XL.HDL.C 0.014 −0.164,0.477
9 Serum.TG,XL.HDL.C 0.014 −0.169,0.465
10 S.HDL.TG,XL.HDL.C 0.013 −0.18,0.415
Results are given after excluding genetic variants in the APOE, FUTC, and LIPC regions. θ^γ is the causal effect estimate for a speciﬁc model
HDL.D HDL diameter, IDL.TG triglycerides in IDL, L.HDL.C total cholesterol in large HDL, LDL.D LDL diameter, Serum.C serum total cholesterol, Serum.TG serum total triglycerides, S.VLDL.C total
cholesterol in small VLDL, S.VLDL.TG triglycerides in small VLDL, XS.VLDL.TG triglycerides in very small VLDL, XL.HDL.C total cholesterol in very large HDL
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Fig. 5 Diagnostic plot for inﬂuential genetic variants. Plotting the
predicted associations with AMD based on the model including XL.HDL.C
(x-axis) against the observed associations with AMD (y-axis) showing all
n ¼ 148 genetic variants, where the colour code shows Cook's distance for
the genetic variants. This is the highest-ranking model on omission of
outlying and inﬂuential genetic variants from the analysis. Note rs26134 in
the LIPC gene region which has an anomalous direction of association with
AMD risk in contrast to all other genetic variants.
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that a majority of instruments is valid, but without prior
knowledge which are the valid instruments. In multivariable MR,
ideally one would like to perform model selection and outlier
detection simultaneously. In addition, we search for genetic var-
iants that are inﬂuential points. While these may not necessary be
pleiotropic, we suggest removing such variants as a sensitivity
analysis to judge whether the overall ﬁndings from the approach
are dominated by a single variant. Findings are likely to be more
reliable when they are evidenced by multiple genetic variants.
One necessary future development is post-selection inference31,32
in the high-dimensional multivariable MR framework. MR-BMA
does not provide unbiased causal effect estimates. Re-ﬁtting an
unbiased multivariable MR model after risk factor selection
would ignore the uncertainty of the selection and consequently
not provide valid inferences.
In conclusion, we introduce here MR-BMA, the ﬁrst approach
to perform risk factor selection in multivariable MR, which can
identify causal risk factors from a high-throughput experiment.
MR-BMA can be used to determine which out of a set of related
risk factors with common genetic predictors are the causal drivers
of disease risk.
Methods
Mendelian randomization data input: summarized data set-up. One of the key
features of MR is that the approach can be performed using summarised data on
genetic associations—beta-coefﬁcients and their standard errors from univariate
regression analyses. No access to individual-level genotype data is needed. In addition,
these association estimates can be derived from different samples. In two-sample MR,
the genetic associations with the risk factor are derived from one sample and the
genetic associations with the outcome from another sample26. The use of summarised
data in two-sample MR allows the sample size to be maximised by integrating data
from large meta-analyses including hundreds of thousands of participants.
We assume the context of two-sample MR with summarized data33. For each
genetic variant i ¼ 1; ¼ ; n and each risk factor j ¼ 1; ¼ ; d, we take the beta-
coefﬁcient β?Xij and standard error seðβ
?
Xij
Þ from a univariable regression in which the
risk factor Xj is regressed on the genetic variant Gi in sample one, and beta-
coefﬁcient β?Yi and standard error seðβ
?
Yi
Þ from a univariable regression in which the
outcome Y is regressed on the genetic variant Gi in sample two. For simplicity of
notation, although the beta-coefﬁcients are estimates, we omit the conventional “hat”
notation and treat the beta-coefﬁcients as observed data points. When considering
multiple risk factors, we construct a matrix of beta-coefﬁcients β?X of dimension
n ´ d, where d is the number of risk factors and n is the number of genetic variants.
We assume that the genetic effects on risk factors and on the outcome are linear
and homogeneous across the population, and identical between the two samples34.
Furthermore, we assume that the n genetic variants selected as instrumental
variables are independent, an assumption common in MR studies. This is usually
achieved by including only the lead genetic variant from each gene region in the
analysis. Finally, we assume that genetic association estimates are derived from two
distinct samples with no overlap between the samples. These assumptions can all
be relaxed to some extent if the goal is causal inference rather than causal
estimation; see ref. 35 for details.
Multivariable Mendelian randomization and the linear model. Multivariable
MR is an extension of the standard MR paradigm (Fig. 1) to model not one, but
multiple risk factors as illustrated in Fig. 2. Univariable MR can be cast as a
weighted linear regression model in which the genetic associations with the out-
come β?Yi are regressed on the genetic associations with the risk factor β
?
Xi
in order
to estimate the total effect θ of the risk factor X on the outcome Y36
β?Yi ¼ θβ
?
Xi
þ ϵi; ϵi  Nð0; seðβ?Yi Þ
2Þ: ð1Þ
In multivariable MR, the genetic associations with the outcome are regressed on
the genetic associations with all the j ¼ 1; ¼ ; d risk factors10
β?Yi ¼ θ1β
?
Xi1
þ θ2β?Xi2 þ ¼ þ θdβ
?
Xid
þ ϵi; ϵi  Nð0; seðβ?Yi Þ
2Þ: ð2Þ
Weights in these regression models are proportional to inverse of the variance
of the genetic association with the outcome (seðβ?Yi Þ
2). This is to ensure that
genetic variants having more precise association estimates receive more weight in
the analysis. The same weighting can also be achieved by standardising the
association estimates, by dividing β?Yi and β
?
Xi
by seðβ?Yi Þ. In the following
derivations, we assume that βYi ¼ β
?
Yi
=seðβ?Yi Þ and βXi ¼ β
?
Xi
=seðβ?Yi Þ are
standardised, so that the variances of the ϵi terms are all 1. To account for
heterogeneity in the regression equation, we can use a multiplicative random effects
model, which increases the variance of the error terms by a multiplicative factor37.
Our parameter of interest is the vector of regression coefﬁcients θ ¼ fθ1; ¼ ; θdg.
These are the direct causal effects of the risk factors in turn on the outcome when
all the other risk factors in the model are held constant13. In contrast, univariable
Mendelian randomization using genetic variants that are instrumental variables for
the speciﬁc risk factor of interest estimates the total effect of the risk factor on the
outcome. The direct effect will differ from the total effect if the effect of the risk
factor is mediated via another risk factor included in the model12. We illustrate the
difference between the direct and total effect using directed acyclic graphs in
Supplementary Fig. 1. In some cases (such as to identify the proximal risk factor to
the outcome), the direct effect is of interest; in other cases (such as to evaluate the
potential impact of intervening on a risk factor), it is the total effect that is truly of
interest13.
Choosing genetic variants as instruments. In multivariable MR, a genetic variant
is a valid instrumental variable if the following criteria hold:
IV1 Relevance: The variant is associated with at least one of the risk factors.
IV2 Exchangeability: The variant is independent of all confounders of each of
the risk factor–outcome associations.
IV3 Exclusion restriction: The variant is independent of the outcome
conditional on the risk factors and confounders.
One of the main differences of multivariable MR compared with univariable MR is
the relaxation of the exclusion restriction condition. In contrast to univariable MR,
multivariable MR allows for measured pleiotropy14 via any of the observed risk
factors. Hence the instrumental variable assumptions are more likely to be satisﬁed
for multivariable MR than for univariable MR for a given choice of genetic variants.
It is not necessary for every genetic variant to be associated with all the risk
factors, although if no genetic variants are associated with a particular risk factor,
then the causal effect of that risk factor cannot be identiﬁed. This would also occur
if the genetic associations with two risk factors were exactly proportional. For
precise identiﬁcation of causal risk factors, it is necessary to have some variants that
are more strongly associated with particular risk factors than others12. More
precisely a risk factor can be included into the analysis if the following criteria
(RF1–RF2) hold:
RF1 Relevance: The risk factor needs to be strongly instrumented by at least one
genetic variant included as instrumental variable.
RF2 No multi-collinearity: The genetic associations of any risk factor included
cannot be linearly explained by the genetic associations of any other risk factor
or by the combination of genetic associations of multiple other risk factors
included in the analysis.
The study design and in particular the selection of genetic variants as IVs are
the most important steps for multivariable MR and great care needs to be taken
when designing the study and also when reporting the study design. All
interpretation of the results is conditional on the genetic variants selected as IVs.
We initially assume that all genetic variants are valid instruments. There is an
emerging literature27,38 on how to perform robust MR analysis in the presence of
invalid instruments; similar extensions can be adapted for multivariable MR14.
Risk factor selection as variable selection in the linear model. We consider the
situation in which we have a set of genetic variants that are instrumental variables
for a set of risk factors, and we want to select which of those risk factors are causes
of the outcome. Our implicit prior belief is that not all of the risk factors are
causally related to the outcome and that there are some true causal risk factors
(signal) and some risk factors which do not have an effect (noise). We formulate
the selection of risk factors in two-sample multivariable MR as a variable selection
task in the linear regression framework. In order to model the correlation between
risk factors we base our likelihood on a Gaussian distribution
βYjβX; θ; τ  N βXθ;
1
τ
 
: ð3Þ
Following the D2 prior speciﬁcations as introduced in ref.
39, we use the following
conjugate priors for the causal effects θ, the residual error ϵ, and the precision τ
θ  Nð0; ν=τÞ
ϵ  N 0; 1
τ
 
τ  Γðκ=2; λ=2Þ;
ð4Þ
where ν ¼ diagðσ2Þ is the diagonal variance matrix of the causal effects (inde-
pendence prior), and the precision τ is assumed to follow a Gamma distribution
with hyperparameters κ as the shape and λ as the scale parameter. Next, we
introduce a binary indicator γ of length d that indicates which risk factors are
selected and which ones are not
γj ¼
1; if the jth risk factor is selected;
0 otherwise:

ð5Þ
The indicator γ encodes a speciﬁc regression modelMγ that includes the risk factors
as indicated in γ. A model Mγ can include one or a combination of multiple risk
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factors. To evaluate the evidence of a speciﬁc modelMγ , we calculate the Bayes factor
for model Mγ against the null model that does not include an intercept or any risk
factor. The Bayes factor BFðMγÞ has the following closed form representation
BFðMγÞ ¼
jΩj1=2
jνγj1=2
βtYβY ΘtΩ1Θ
βtYβY
 n=2
; ð6Þ
where Θ ¼ ΩβtXγ βY is the causal effect estimate and Ω ¼ ðν1γ þ β
t
Xγ
βXγ Þ
1
is the
inverse of the shrinkage covariance between the genetic associations of the risk
factors. For a detailed derivation of the Bayes factor we refer to the Supplementary
Methods in the Supplementary Information.
Prior speciﬁcation. Another important aspect is the prior for the model size k,
which we model using a Binomial distribution
PrðK ¼ kÞ ¼ d
k
 
pkð1 pÞdk: ð7Þ
This requires choosing the probability p of including a risk factor in the model
according to prior assumptions regarding the sparsity of the results. We recom-
mend to select p according to the expected a priori model size, which is p ´ d.
Currently, all risk factors are assumed to have the same prior probability, and thus
the probability of all models of the same size k is equal. The prior of a speciﬁc
model Mγ of size k is deﬁned as
pðMγÞ ¼
d
k
 1
PrðK ¼ kÞ ¼ pkð1 pÞdk: ð8Þ
The second important aspect is the prior for the variance of the risk factors
ν ¼ diagðσ2Þ, where we assume that all risk factors have the same prior variance σ2.
Large values of σ2 would favour strong causal effects of the risk factors on the
outcome. Following ref. 39 we initially set σ2 ¼ 0:25, but sensitivity of the results
with respect to this prior should be investigated. The parameter can be speciﬁed in
the implementation of MR-BMA. In the applied example we perform a sensitivity
analysis for this important parameter.
Posterior calculation and marginal inclusion probability of a risk factor. Let Γ
be the space of all possible combinations of risk factors. The posterior probability
(PP) of a model Mγ can be expressed by the prior probability (8) and the Bayes
factor (6) of model Mγ is
PPðMγjβY; βXÞ ¼
pðMγÞBFðMγÞP
γ2ΓpðMγÞBFðMγÞ
: ð9Þ
In high-dimensional variable selection, the evidence for one particular model
can be small because the model space is very large and many models might have
comparable evidence. This is why MR-BMA uses Bayesian model averaging (BMA)
and computes for each risk factor j its marginal inclusion probability (MIP), which
is deﬁned as the sum of the posterior probabilities over all models where the risk
factor is present
MIPðj ¼ 1jβY; βXÞ ¼
P
γ2ΓIðγj ¼ 1ÞpðMγÞBFðMγÞP
γ2ΓpðMγÞBFðMγÞ
; ð10Þ
where Iðγj ¼ 1Þ equals 1 if risk factor j is part of the model and 0 otherwise.
An exhaustive evaluation of all possible combinations of risk factors is
computationally prohibitive already for a moderate number of risk factors (d > 20).
To alleviate this issue we have implemented a shotgun stochastic search
algorithm40 that evaluates all combinations of risk factors with a non-negligible
contribution to the calibration factor
P
γ2ΓpðMγÞBFðMγÞ in Eq. (9). This
algorithm is based on the assumption that the majority of combinations of risk
factors have a posterior probability close to zero and do not need to be considered
when computing the calibration factor in the denominator of Eqs. (9) and (10).
Causal estimation. We derive the estimates for the causal effects θ^γ of model Mγ
as
θ^γ ¼ ΩβtXγ βY ¼ ðν
1
γ þ βtXγ βXγ Þ
1
βtXγ βY; ð11Þ
which is closely related to the regression coefﬁcient in Ridge regression. Adding the
diagonal matrix ν1γ stabilises the inversion and makes the estimate more robust to
strong correlation among risk factors. There can be strong correlation between
candidate risk factors as seen in the genetic correlation matrices in the applied
examples as illustrated in Supplementary Figs. 2 and 11, which makes it important
to stabilise the causal estimate.
The model-averaged causal estimate (MACE) for risk factor j from the MR-
BMA approach is
θ^MACEðjÞ ¼
X
γ2Γ
Iðγj ¼ 1ÞPPðMγjβY; βXÞθ^γ: ð12Þ
Both θ^γ and θ^MACE are conservative estimates of the true causal effect. They are
biased towards the Null if there is a causal effect and unbiased otherwise. We
therefore only recommend to interpret the direction of effect and the magnitude of
these causal effect estimates in comparison with the effects of other risk factors.
MR-BMA ranks and prioritises risk factors according to their marginal
inclusion probability and estimates the MACE as deﬁned in Eq. (12). As an
alternative approach, we also consider selecting the ‘best model’ based on the
individual model posterior probabilities as deﬁned in Eq. (9).
Detection of invalid and inﬂuential instruments. Invalid instruments may be
detected as outliers with respect to the ﬁt of a speciﬁc linear model Mγ . We
recommend to check the best individual models for outliers by visual inspection of
the scatterplot of the predicted associations based on Mγ with the outcome β^Y ¼
βXγ θ^γ against the actual observed βY . If a genetic variant is detected consistently as
an outlier in several of the top models, it may be advisable to explore the analyses
excluding that outlying variant from the analysis. To quantify outliers we use the
Q-statistic, which is an established tool for identifying heterogeneity in meta-
analysis15. It is deﬁned as the sum of the residual vector q, which is the squared
difference between the observed and predicted association with the outcome
Q ¼
Xn
i¼1
qi ¼
Xn
i¼1
ðβYi  β^Yi Þ
2
: ð13Þ
We note that Eq. (13) is deﬁned on the weighted coefﬁcients βYi . When con-
sidering the unweighted coefﬁcients β?Yi the Q-statistic
12 is deﬁned as
Q ¼
Xn
i¼1
qi ¼
Xn
i¼1
1
seðβ?Yi Þ
2 ðβ?Yi  β^
?
Yi
Þ2; ð14Þ
with ﬁrst order weighting equal to 1
seðβ?Yi Þ
2
41.
The individual element qi measures the heterogeneity of genetic variant i for a
particular model Mγ . We refer to qi as the q-statistic, and use this to evaluate if
speciﬁc genetic variants are outliers to the model ﬁt.
Even if there are no outliers, it is advisable to check for inﬂuential observations
and re-run the approach omitting a particular inﬂuential variant from the analysis.
If a particular genetic variant has a strong association with the outcome, then it
may have undue inﬂuence on the variable selection, leading to a model that ﬁts that
particular observation well, but other observations poorly. To quantify inﬂuential
observations for a particular model Mγ we suggest to use Cook’s distance
16
Cdi ¼
qi
s2d
hi
ð1 hiÞ2
; ð15Þ
where hi is the ith diagonal element of the hat matrix
H ¼ βXγ ðν1γ þ β
t
Xγ
βXγ Þ
1
βtXγ , and s
2 ¼ 1nd ϵtϵ is the mean squared error of the
regression model. Following ref. 42, we recommend to use the median of a central
F-distribution with d and n d degrees of freedom as a threshold, and remove
variants that have a Cook’s distance which exceeds this value.
Impact of weak instrument bias. In the following presentation, we consider two
risk factors with observed genetic associations βX1 and βX2 , which are a sum of the
true genetic associations βyX1 and β
y
X2
and an additional error term ϵ1 and ϵ2,
respectively, i.e.
βX1 ¼ β
y
X1
þ ϵ1
βX2 ¼ β
y
X2
þ ϵ2:
From this we deﬁne λ1 ¼ varðϵ1ÞvarðβyX1 Þ
as the ratio of the uncertainty in the estimates of the
genetic associations (varðϵ1Þ) over the variability of the true genetic associations
varðβyX1 Þ, and we deﬁne λ2 similarly. Further let ρ be the correlation between βX1 and
βX2 , and let θ1 and θ2 be the true direct effect of X1 on Y and X2 on Y , respectively.
Following the measurement error literature43, we derive the induced bias of the IVW
estimates of the true causal effects θ1 and θ2, respectively, as
θ^1 ¼ θ1 
θ1λ1  ρθ2λ2
1 ρ
θ^2 ¼ θ2 
θ2λ2  ρθ1λ1
1 ρ ;
where θ^1 and θ^2 are the expected values of the effects for the mismeasured genetic
association estimates. Looking closer at λ, the variability across variants of the true
genetic associations, varðβyXÞ, is related to instrument strength. Thus the induced bias
will be smaller the stronger the instruments. At the same time the uncertainty of the
genetic association estimates, varðϵÞ, decreases when increasing the sample size. If the
genetic associations with the risk factors are estimated with different degrees of
uncertainty, then bias could be more considerable. Analogous to differential mea-
surement error, risk factors with more precisely estimated genetic associations would
be prioritized in the regression model. In our application, all risk factors are measured
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on the same high-throughput platform and on the same sample size, thus reducing
the impact of weak instrument bias to inﬂuence the ranking of risk factors.
Simulation study. To evaluate the performance of MR-BMA, we perform a
simulation study taking genetic associations with risk factors from two real data
sets, the ﬁrst one based on genetic associations with NMR metabolites11 and sec-
ondly on genetic associations with blood cell traits4. Further information on the
data sets and pre-processing is given in the next sections. We simulate genetic
associations with the outcome βY based on a subset of risk factors selected at
random, which we refer to as the ‘true’ risk factors. We investigate three different
scenarios and six sets of parameter values per scenario:
Size of the data set: small (d ¼ 12 NMR metabolites selected at random), large
(d ¼ 92 all NMR metabolites available), and moderate (d ¼ 33 all blood cell
traits available) number of risk factors included.
Number of true risk factors: (Setting A) four risk factors have an effect of
θ ¼ 0:3, the other risk factors have no effect; (Setting B) four risk factors have
an effect of θ ¼ 0:3, and another four risk factors have an effect of θ ¼ 0:3,
the other risk factors have no effect.
Proportion of variance in the outcome explained by the risk factors: R2 ¼
0:1; 0:3; 0:5 which deﬁnes the variance of the error.
We compare six different analysis methods:
Multivariable inverse-variance weighted (IVW) regression (Eq. (2))10
Least-angle regression (Lars) as L1 regularised regression17
Lasso as L1 regularised regression18
Elastic Net as L1 and L2 regularised regression18
MR-BMA using marginal inclusion probabilities (Eq. (10))
Bayesian best model selection using posterior probabilities of individual models
(Eq. (9))
Both Lars17 and Lasso are versions of L1 regularised linear regression, and
Elastic Net is a mixture of a L1 and L2 regularised linear regression, all of which
have been devised for variable selection in high-dimensional data. We use here the
Lars implementation17 and for Lasso and Elastic Net we use the glmnet18
implementation. For all regularised regression methods, we use cross-validation
(CV) to tune the regularisation parameter to achieve the minimum cross-validation
MSE. For the small risk factor space including 12 NMR metabolites, the MR-BMA
approach is performed using an exhaustive search of all possible models with prior
probability of a risk factor to be included set to p ¼ 0:5, while for the moderate and
large risk factor space of d ¼ 33 blood cell traits and d ¼ 92 NMR metabolites we
employ the stochastic search with 10,000 iterations and p ¼ 0:1. This reﬂects an
expected a priori model size of six for the small risk factor space and around three
for the blood cell traits and nine for the high-dimensional NMR metabolite setting.
The prior variance σ2 is ﬁxed to 0.25.
Data pre-processing for NMR metabolites for simulation. The ﬁrst data
resource used for the simulation and application is publicly available summarized
data on genetic associations with risk factors derived from a NMR metabolite
GWAS11 from http://computationalmedicine.ﬁ/data#NMR_GWAS. All of the
metabolites were inverse rank-based normal transformed, so the association esti-
mates are all in standard deviation units. In order to avoid selection bias, we choose
genetic variants based on an external dataset. As the majority of the metabolite
measures relates to lipids, we take n ¼ 150 independent genetic variants that are
associated with any of three composite lipid measurements (LDL cholesterol, tri-
glycerides, or HDL cholesterol) at a genome-wide level of signiﬁcance (p-value
(two-sided) <5 ´ 108) in a large meta-analysis of the Global Lipids Genetics
Consortium19. We extract beta-coefﬁcients and standard errors of genetic asso-
ciations for the 150 genetic variants and the 118 available metabolites. Next, we
compute the genetic correlation structure between metabolites based on the n ¼
150 instrumental variables and exclude at random one of each pair of metabolites
that are in stronger correlation than jrj> 0:99. For the simulation study each risk
factor is scaled to have unit variance so all risk factors have an equal prior chance of
being selected. Our ﬁnal dataset βX for the simulation study comprises associations
of d ¼ 92 metabolites measured on n ¼ 150 genetic variants. This allows us to
investigate risk factor selection for a realistic genetic correlation structure between
metabolites (Supplementary Fig. 2) and distribution of the regression coefﬁcients.
Data pre-processing for blood cell traits for simulation. As a secondary data
resource, we use publicly available summary data from the GWAS catalog https://
www.ebi.ac.uk/gwas/ on 36 blood cell traits measured on nearly 175,000 partici-
pants4. Using all genetic variants that were genome-wide signiﬁcant for any blood
cell trait we have n ¼ 2667 genetic variants as instrumental variables. There were
eight pairs of blood cell traits with genetic correlation >0:99. After removing three
composite traits (sum of eutrophil and eosinophil counts, granulocyte count, and
sum of basophil and neutrophil counts) from further analysis, there was no pair of
blood cell traits with greater genetic correlation than 0.99. The respective corre-
lation matrix is shown in Supplementary Fig. 11. The ﬁnal dataset used for the
simulation consists of d ¼ 33 blood cell traits as potential risk factors measured on
n ¼ 2667 genetic variants (pruned at r2 < 0:8). For the simulation study each risk
factor is scaled to have unit variance so all risk factors have an equal prior chance of
being selected. We consider all d ¼ 33 risk factors jointly for the simulation and
consequently the simulation study has a realistic correlation structure between
genetic associations of various blood cell traits (Supplementary Fig. 11) and a
realistic distribution of regression coefﬁcients.
Data pre-processing and analysis for applied example of age-related macular
degeneration. In the applied example we demonstrate how MR-BMA can be
used to select metabolites as causal risk factors for age-related macular degen-
eration (AMD). As risk factors we consider a range of circulating metabolites
measured by NMR spectroscopy11. We use the same lipid-related genetic var-
iants as in the simulation study. We restrict the risk factor space to include only
lipoprotein measurements on total cholesterol content, triglyceride content, and
particle diameter. For the various fatty acid measurements, we only included
total fatty acids. Other lipid characteristics were highly correlated with the
selected lipid measurements and including all of the lipid measurements would
introduce multi-collinearity (RF2). As a next step we excluded all metabolite
measures that did not have a single genetic variant that is genome-wide sig-
niﬁcant to meet the relevance criterion RF1. None of the remaining d ¼ 30
metabolite measures have correlations in their genetic associations of jrj> 0:985
(Supplementary Fig. 2). Genetic associations with the outcome are taken from
the latest GWAS meta-analysis on AMD9 including 16; 144 patients and 17; 832
controls which is available from http://csg.sph.umich.edu/abecasis/public/
amd2015/. To synchronise the genetic data on the metabolite risk factors and the
AMD outcome, we match the effect alleles and we remove two genetic variants
missing in the AMD data, so that the overall analysis includes n ¼ 148 variants.
Finally, we use the Ensembl Variant Effect Predictor44 to annotate the genetic
variants to the gene that is most likely affected.
We run MR-BMA including all n ¼ 148 available genetic variants on the
d ¼ 30 metabolite associations using p ¼ 0:1 as prior probability, σ2 ¼ 0:25 as
prior variance, a maximum model size of 12 risk factors, and with 100,000
iterations in the shotgun stochastic search. To check the impact of the prior choice
we ﬁrst vary the prior probability (Supplementary Table 10) of selecting a risk
factor from p ¼ 0:01 to 0.3 reﬂecting 0.3-9.0 expected causal risk factors. This
choice alters the posterior probabilities of various individual models, but the overall
marginal inclusion probabilities of the risk factors are relatively stable. Finally, we
vary the prior variance σ2 from 0.01 to 0.49, which does not change the ranking
(Supplementary Table 11).
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
All data used in our study is in the public domain. Our study is based on publicly
available summary-level data on genetic associations from the International AMD
Genetics consortium http://amdgenetics.org/, the GWAS catalog https://www.ebi.ac.uk/
gwas/, and MAGNETIC NMR-GWAS http://www.computationalmedicine.ﬁ/data. Pre-
processed summary-level data used as input for this study is available from https://
github.com/verena-zuber/demo_AMD.
Code availability
R-code for MR-BMA (R version > 3:4:2, MIT license) and all other multivariable MR
approaches (IVW, lars, lasso and elastic net) is provided on https://github.com/verena-
zuber/demo_AMD. Moreover, we provide markdown scripts and the summary-level data
on AMD and NMR metabolites as presented in the applied example on https://github.
com/verena-zuber/demo_AMD. This allows the reader to reproduce all results and
ﬁgures of the applied example and adapt the presented methodology on risk factor
selection in multivariable MR into their own research.
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